Wedbush analyst Robert Driscoll raised the firm’s price target on Ideaya Biosciences to $40 from $35 and keeps an Outperform rating on the shares. The firm has increased confidence in the IDE397/AMG 193 combination, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $35 from $30 at Oppenheimer
- IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
- Ideaya Biosciences reports Q2 EPS (50c), consensus (56c)
- DraftKings upgraded, Home Depot downgraded: Wall Street’s top analyst calls
- Ideaya Biosciences initiated with an Outperform at SVB Securities